1887

Abstract

Newcastle disease virus (NDV) has been extensively explored as a vector for vaccine and oncolytic therapeutic development. In conventional NDV-based vectors, the transgene is arranged as a separate transcription unit in the NDV genome. Here, we expressed haemagglutinin protein (HA) of an avian influenza virus using an NDV vector design in which the transgene ORF is encoded in-frame with the ORF of an NDV gene. This arrangement does not increase the number of transcription units in the NDV genome, and imposes a selection pressure against mutations interrupting the transgene ORF. We placed the HA ORF upstream or downstream of N, M, F and HN ORFs of NDV so that both proteins are encoded in-frame and are separated by either a self-cleaving 2A peptide, furin cleavage site or both. Only constructs in which HA was placed downstream of the NDV HN were viable. These constructs expressed the transgene at a higher level compared to the vector encoding the same transgene in the same position in the NDV genome but as a separate transcription unit. Furthermore, the transgene expressed in one ORF with the NDV protein proved to be more stable over multiple passages. Thus, this design may be useful for applications where the stability of the transgene expression is highly important for a recombinant NDV vector.

Funding
This study was supported by the:
  • Maryland Agricultural Experimental Station (Award MD-VTMD-201175)
    • Principle Award Recipient: GeorgeA Belov
  • NIAID (Award R21AI153976)
    • Principle Award Recipient: GeorgeA Belov
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001761
2022-06-27
2024-03-28
Loading full text...

Full text loading...

References

  1. Newcastle disease, chapter 2.3.14. OIE Terrestrial Manual 2012: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals Paris: World Organisation for Animal Health; 2012 pp 576–589
    [Google Scholar]
  2. Alexander DJ. Newcastle Disease. In Alexander DJ. eds Newcastle Disease in Free-Living and Pet Birds Boston, MA: Springer; 1988 pp 197–246
    [Google Scholar]
  3. Miller PJ, Koch G. Diseases of Poultry 2020
    [Google Scholar]
  4. Thornton DH, Hopkins IG, Hebert CN. Potency of live Newcastle disease vaccines. Avian Pathol 1980; 9:457–464 [View Article] [PubMed]
    [Google Scholar]
  5. Sato H, Oh-hira M, Ishida N, Imamura Y, Hattori S et al. Molecular cloning and nucleotide sequence of P, M and F genes of Newcastle disease virus avirulent strain D26. Virus Res 1987; 7:241–255 [View Article] [PubMed]
    [Google Scholar]
  6. Battisti AJ, Meng G, Winkler DC, McGinnes LW, Plevka P et al. Structure and assembly of a paramyxovirus matrix protein. Proc Natl Acad Sci U S A 2012; 109:13996–14000 [View Article] [PubMed]
    [Google Scholar]
  7. Morrison T, McQuain C, McGinnes L. Complementation between avirulent Newcastle disease virus and a fusion protein gene expressed from a retrovirus vector: requirements for membrane fusion. J Virol 1991; 65:813–822 [View Article] [PubMed]
    [Google Scholar]
  8. Heminway BR, Yu Y, Galinski MS. Paramyxovirus mediated cell fusion requires co-expression of both the fusion and hemagglutinin-neuraminidase glycoproteins. Virus Res 1994; 31:1–16 [View Article] [PubMed]
    [Google Scholar]
  9. Horikami SM, Curran J, Kolakofsky D, Moyer SA. Complexes of Sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro. J Virol 1992; 66:4901–4908 [View Article] [PubMed]
    [Google Scholar]
  10. Vidal S, Curran J, Kolakofsky D. A stuttering model for paramyxovirus P mRNA editing. EMBO J 1990; 9:2017–2022 [PubMed]
    [Google Scholar]
  11. Poole E, He B, Lamb RA, Randall RE, Goodbourn S. The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 2002; 303:33–46 [View Article] [PubMed]
    [Google Scholar]
  12. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A 2004; 101:17264–17269 [View Article] [PubMed]
    [Google Scholar]
  13. Park M-S, García-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003; 77:9522–9532 [View Article] [PubMed]
    [Google Scholar]
  14. Yang Y, Xue J, Teng Q, Li X, Bu Y et al. Mechanisms and consequences of Newcastle disease virus W protein subcellular localization in the nucleus or mitochondria. J Virol 2021JVI.02087-20 [View Article] [PubMed]
    [Google Scholar]
  15. Samal SK. Newcastle disease virus. In Samal SK. eds Avian Virology Norfolk, UK: Caister Academic Press Limited; 2019 pp 43–85
    [Google Scholar]
  16. Wignall-Fleming EB, Hughes DJ, Vattipally S, Modha S, Goodbourn S et al. Analysis of paramyxovirus transcription and replication by high-throughput sequencing. J Virol 2019; 93:17 [View Article] [PubMed]
    [Google Scholar]
  17. Collins PL, Wertz GW. cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A 1983; 80:3208–3212 [View Article] [PubMed]
    [Google Scholar]
  18. Iverson LE, Rose JK. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 1981; 23:477–484 [View Article] [PubMed]
    [Google Scholar]
  19. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 2007; 104:9788–9793 [View Article] [PubMed]
    [Google Scholar]
  20. DiNapoli JM, Yang L, Suguitan A Jr, Elankumaran S, Dorward DW et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 2007; 81:11560–11568 [View Article] [PubMed]
    [Google Scholar]
  21. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010; 84:1489–1503 [View Article] [PubMed]
    [Google Scholar]
  22. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL et al. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010; 29:17–25 [View Article] [PubMed]
    [Google Scholar]
  23. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13:221–228 [View Article] [PubMed]
    [Google Scholar]
  24. Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M et al. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 2005; 79:13275–13284 [View Article] [PubMed]
    [Google Scholar]
  25. Hu ZL, Ni J, Cao YZ, Liu XF. Newcastle Disease Virus as A Vaccine Vector for 20 Years: A Focus on Maternally Derived Antibody Interference. Vaccines (Basel) 2020; 8:E222 [View Article] [PubMed]
    [Google Scholar]
  26. Bello MB, Yusoff K, Ideris A, Hair-Bejo M, Jibril AH et al. Exploring the prospects of engineered newcastle disease virus in modern vaccinology. Viruses 2020; 12:E451 [View Article] [PubMed]
    [Google Scholar]
  27. Kim SH, Samal SK. Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. Viruses 2016; 8:E183 [View Article] [PubMed]
    [Google Scholar]
  28. Huang ZM, Liu MY, Huang Y. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus. Discov Med 2020; 30:39–48 [PubMed]
    [Google Scholar]
  29. Burman B, Pesci G, Zamarin D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers (Basel) 2020; 12:E3552 [View Article] [PubMed]
    [Google Scholar]
  30. Viktorova EG, Khattar SK, Kouiavskaia D, Laassri M, Zagorodnyaya T et al. Newcastle disease virus-based vectored vaccine against poliomyelitis. J Virol 2018; 92:17 [View Article] [PubMed]
    [Google Scholar]
  31. Yu Q, Li Y, Dimitrov K, Afonso CL, Spatz S et al. Genetic stability of a Newcastle disease virus vectored infectious laryngotracheitis virus vaccine after serial passages in chicken embryos. Vaccine 2020; 38:925–932 [View Article] [PubMed]
    [Google Scholar]
  32. Manoharan VK, Khattar SK, LaBranche CC, Montefiori DC, Samal SK. Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus. Sci Rep 2018; 8:8952 [View Article] [PubMed]
    [Google Scholar]
  33. Barr JN, Fearns R. How RNA viruses maintain their genome integrity. J Gen Virol 2010; 91:1373–1387 [View Article] [PubMed]
    [Google Scholar]
  34. Lejeune F. Nonsense-Mediated mRNA Decay, a finely regulated mechanism. Biomedicines 2022; 10:141 [View Article] [PubMed]
    [Google Scholar]
  35. Wen G, Chen C, Guo J, Zhang Z, Shang Y et al. Development of a novel thermostable Newcastle disease virus vaccine vector for expression of a heterologous gene. J Gen Virol 2015; 96:1219–1228 [View Article] [PubMed]
    [Google Scholar]
  36. Shirvani E, Paldurai A, Varghese BP, Samal SK. Contributions of HA1 and HA2 subunits of highly pathogenic avian influenza virus in induction of neutralizing antibodies and protection in chickens. Front Microbiol 2020; 11:1085 [View Article] [PubMed]
    [Google Scholar]
  37. Huang ZH, Krishnamurthy S, Panda A, Samal SK. High-level expression of a foreign gene from the most 3’-proximal locus of a recombinant Newcastle disease virus. J Gen Virol 2001; 82:1729–1736 [View Article] [PubMed]
    [Google Scholar]
  38. Samuel AS, Subbiah M, Shive H, Collins PL, Samal SK. Experimental infection of hamsters with avian paramyxovirus serotypes 1 to 9. Vet Res 2011; 42:38 [View Article] [PubMed]
    [Google Scholar]
  39. Shirvani E, Varghese BP, Paldurai A, Samal SK. A recombinant avian paramyxovirus serotype 3 expressing the hemagglutinin protein protects chickens against H5N1 highly pathogenic avian influenza virus challenge. Sci Rep 2020; 10:2221 [View Article] [PubMed]
    [Google Scholar]
  40. Elbehairy MA, Khattar SK, Samal SK. Recovery of recombinant avian paramyxovirus type-3 strain wisconsin by reverse genetics and its evaluation as a vaccine vector for chickens. Viruses 2021; 13:316 [View Article] [PubMed]
    [Google Scholar]
  41. Donnelly MLL, Hughes LE, Luke G, Mendoza H, Ten Dam E et al. The “cleavage” activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring “2A-like” sequences. J Gen Virol 2001; 82:1027–1041 [View Article] [PubMed]
    [Google Scholar]
  42. Donnelly MLL, Luke G, Mehrotra A, Li X, Hughes LE et al. Analysis of the aphthovirus 2A/2B polyprotein “cleavage” mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal “skip.”. J Gen Virol 2001; 82:1013–1025 [View Article] [PubMed]
    [Google Scholar]
  43. Kim JH, Lee S-R, Li L-H, Park H-J, Park J-H et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 2011; 6:e18556 [View Article] [PubMed]
    [Google Scholar]
  44. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3:753–766 [View Article] [PubMed]
    [Google Scholar]
  45. Shiryaev SA, Chernov AV, Golubkov VS, Thomsen ER, Chudin E et al. High-resolution analysis and functional mapping of cleavage sites and substrate proteins of furin in the human proteome. PLoS One 2013; 8:e54290 [View Article] [PubMed]
    [Google Scholar]
  46. Bertram S, Glowacka I, Steffen I, Kühl A, Pöhlmann S. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev Med Virol 2010; 20:298–310 [View Article] [PubMed]
    [Google Scholar]
  47. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL. Nonsegmented negative-strand viruses as vaccine vectors. J Virol 2006; 80:10293–10306 [View Article] [PubMed]
    [Google Scholar]
  48. Park M-S, Steel J, García-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A 2006; 103:8203–8208 [View Article] [PubMed]
    [Google Scholar]
  49. Chu Z, Gao X, Liu H, Ma J, Wang C et al. Newcastle disease virus selectively infects dividing cells and promotes viral proliferation. Vet Res 2019; 50:27 [View Article] [PubMed]
    [Google Scholar]
  50. Manoharan VK, Varghese BP, Paldurai A, Samal SK. Effect of fusion protein cleavage site sequence on generation of a genotype VII Newcastle disease virus vaccine. PLoS One 2018; 13:e0197253 [View Article] [PubMed]
    [Google Scholar]
  51. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 2008; 6:815–826 [View Article] [PubMed]
    [Google Scholar]
  52. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999; 73:9568–9575 [View Article] [PubMed]
    [Google Scholar]
  53. Jin JH, Zhao J, Ren YC, Zhong Q, Zhang GZ. Contribution of HN protein length diversity to Newcastle disease virus virulence, replication and biological activities. Sci Rep 2016; 6:36890 [View Article] [PubMed]
    [Google Scholar]
  54. Song H, Zhong LP, He J, Huang Y, Zhao YX. Application of Newcastle disease virus in the treatment of colorectal cancer. World J Clin Cases 2019; 7:2143–2154 [View Article] [PubMed]
    [Google Scholar]
  55. Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 2012; 7:347–367 [View Article] [PubMed]
    [Google Scholar]
  56. Cuoco JA, Rogers CM, Mittal S. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. Neurosurg Focus 2021; 50:E8 [View Article] [PubMed]
    [Google Scholar]
  57. Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K et al. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24:644–654 [View Article] [PubMed]
    [Google Scholar]
  58. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70:4297–4309 [View Article] [PubMed]
    [Google Scholar]
  59. Kohno S-I, Luo C, Nawa A, Fujimoto Y, Watanabe D et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther 2007; 14:918–926 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001761
Loading
/content/journal/jgv/10.1099/jgv.0.001761
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error